secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2024-06-12T23:59:59+00:00
Accession:  0001213900-24-052167
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

60 Degrees Pharmaceuticals receives FDA orphan drug designation for tafenoquine to treat acute babesiosis
--------------------------------------------------------------------------------

- FDA granted orphan drug designation for tafenoquine for acute babesiosis; company qualifies for market exclusivity, tax credits, and exemption from certain FDA filing fees.
- Company entered agreement with Tufts Medical Center for first clinical trial in human babesiosis patients; recruitment starts June 13, 2024, with at least 24 hospitalized patients.
- Babesiosis is transmitted by deer ticks; up to 47,600 of ~476,000 annual Lyme patients may be co-infected with Babesia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024052167/0001213900-24-052167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024052167/ea020775201-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-052167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer